Literature DB >> 17032347

Assessing progression to impaired glucose tolerance and type 2 diabetes mellitus.

F Guerrero-Romero1, M Rodríguez-Morán.   

Abstract

BACKGROUND: A prospective evaluation of the relationship between insulin secretion and insulin sensitivity, derived from the fasting state, is needed in clinical practice in order to identify the worsening of glucose metabolism. In this study the authors examine whether the product of insulin sensitivity and insulin secretion, assessed from the fasting state, predicts progression from normal glucose tolerance (NGT) to impaired fasting glucose (IFG) and from impaired glucose tolerance (IGT) to type 2 diabetes mellitus (T2DM).
MATERIALS AND METHODS: A cohort of 300 subjects with NGT and 75 subjects with IGT were followed up over a 5-year period. Insulin sensitivity was calculated using the Belfiore index (B) and insulin secretion by the homeostasis model analysis beta-cell (HOMA-beta cell) index: the product of B-beta is expressed as: (40 x Ins(0) pmol L(-1))/Glu(0) mmol L(-1){[(Glu(0) mmol L(-1)x Ins(0) pmol L(-1)) + 1] - 3.5[(Glu(0) mmol L(-1) x Ins(0) pmol L(-1)) - 1]}, where Glu(0) is fasting glucose and Ins(0) is fasting insulin.
RESULTS: From baseline at the end of the follow-up period, the product B-beta decreased 10.7% and 52.2% in progressors to IGT and T2DM, respectively. The product B-beta predicts the progression from NGT to IGT [relative risk (RR) 2.7, CI(95%) 1.2-9.1] and from IGT to T2DM (RR 5.3, CI(95%) 1.3-8.55). The cut-off point for the product B-beta that better predicts progression from NGT to IGT is 0.25 (sensitivity 88%, specificity 92%) and from IGT to T2DM 0.15 (sensitivity 92%, specificity 95%).
CONCLUSIONS: Adaptation of insulin secretion to compensate for decreased insulin sensitivity during transition to IGT and T2DM can be successfully assessed with simple measures derived from the fasting state. The product B-beta predicts the development to IGT and T2DM.

Entities:  

Mesh:

Year:  2006        PMID: 17032347     DOI: 10.1111/j.1365-2362.2006.01728.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function.

Authors:  Y R Patel; M S Kirkman; R V Considine; T S Hannon; K J Mather
Journal:  J Clin Endocrinol Metab       Date:  2016-08-17       Impact factor: 5.958

2.  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study.

Authors:  Adam G Tabák; Markus Jokela; Tasnime N Akbaraly; Eric J Brunner; Mika Kivimäki; Daniel R Witte
Journal:  Lancet       Date:  2009-06-08       Impact factor: 79.321

Review 3.  Risk assessment tools for identifying individuals at risk of developing type 2 diabetes.

Authors:  Brian Buijsse; Rebecca K Simmons; Simon J Griffin; Matthias B Schulze
Journal:  Epidemiol Rev       Date:  2011-05-27       Impact factor: 6.222

4.  Effects of genetic susceptibility for type 2 diabetes on the evolution of glucose homeostasis traits before and after diabetes diagnosis: data from the D.E.S.I.R. Study.

Authors:  Alain Gautier; Ronan Roussel; Céline Lange; Xavier Piguel; Stéphane Cauchi; Sylviane Vol; Philippe Froguel; Beverley Balkau; Fabrice Bonnet
Journal:  Diabetes       Date:  2011-09-12       Impact factor: 9.461

5.  Unusually rapid beta-cell failure in a patient newly diagnosed with type 2 diabetes presenting acutely with unprovoked severe hyperglycaemic hyperosmolar state: a case report.

Authors:  Joey Yeoh; Judy Chien-Chun Huang; Harriet Cheng; Kenneth Ross Muir
Journal:  Cases J       Date:  2009-08-10

6.  Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.

Authors:  Bernd Richter; Bianca Hemmingsen; Maria-Inti Metzendorf; Yemisi Takwoingi
Journal:  Cochrane Database Syst Rev       Date:  2018-10-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.